Search
Pholcodine
go.drugbank.com/drugs/DB09209ApprovedIllicit[A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008. … Pholcodine is not approved in Canada.
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Nogapendekin alfa, in combination with inbakicept, mimics the actions of IL-15, , stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which
Synonyms: Il-15n72d:il-15rec-su/fc soluble complex i, Fusion protein consisting of il-15n72d and il-15rasu/fcLevoketoconazole
go.drugbank.com/drugs/DB05667Approvedchanges in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections. … [A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalby the presence of ANCAs in the serum. … fragment C5a and its cognate C5aR receptor in AAV.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalPravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. … [L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained.
Products: Lin-pravastatinEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.
Synonyms: N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamideTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging
Rivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. … Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Categories: Compounds used in a research, industrial, or household settingVidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691] … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household setting